| |
| |
|
| Insider
Information: |
Hastings Paul J |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
258,381 |
|
|
Indirect Shares
|
6,636 |
|
|
| Direct
Value |
$264,756 |
|
|
|
Indirect Value
|
$20,505 |
|
|
| Total
Shares |
265,017 |
|
|
| Total
Value |
$285,261 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -131.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Novelion Therapeutics Inc |
NVLN |
President & CEO, Direc... |
2005-04-29 |
9,500 |
|
0 |
Premium* |
|
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
2023-06-14 |
8,374 |
2013-05-15 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2014-06-19 |
0 |
Premium* |
|
|
Protara Therapeutics, Inc |
TARA |
Director |
|
0 |
2016-10-18 |
6,636 |
Premium* |
|
|
Nkarta, Inc. |
NKTX |
|
2024-03-04 |
240,507 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
62 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2021-03-05 |
4 |
S |
$65.88 |
$197,640 |
D/D |
(3,000) |
6,116 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2021-06-04 |
4 |
AS |
$62.19 |
$39,180 |
D/D |
(630) |
5,486 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2021-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,066 |
6,552 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
7,712 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2022-07-11 |
4 |
AS |
$56.95 |
$30,354 |
D/D |
(533) |
7,179 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-05-15 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
14,179 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-05-15 |
4 |
AS |
$41.85 |
$292,950 |
D/D |
(7,000) |
7,179 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-06-05 |
4 |
S |
$38.34 |
$22,237 |
D/D |
(580) |
6,599 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
8,374 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
President & CEO |
• • – |
2005-04-29 |
4 |
B |
$10.77 |
$9,693 |
D/D |
900 |
9,500 |
2.81 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
President & CEOOfficer |
• • – |
2004-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,600 |
|
- |
|
| NKTX |
Nkarta, Inc. |
See RemarksOfficer |
• • – |
2020-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
253,061 |
|
- |
|
62 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
